Rizzo, M, Colletti, A, Penson, PE, Katsiki, N, Mikhailidis, DP, Toth, PP, Gouni-Berthold, I, Mancini, J, Marais, D, Moriarty, P, Ruscica, M, Sahebkar, A, Vinereanu, D, Cicero, AFG, Banach, M, Acosta, J, Al-Khnifsawi, M, Alnouri, F, Amar, F, Atanasov, AG et al, Bajraktari, G, Bhaskar, S, Bielecka-Dąbrowa, A, Bjelakovic, B, Bruckert, E, Bytyçi, I, Cafferata, A, Ceska, R, Chlebus, K, Collet, X, Daccord, M, Descamps, O, Djuric, D, Durst, R, Ezhov, MV, Fras, Z, Gaita, D, Hernandez, AV, Jones, SR, Jozwiak, J, Kakauridze, N, Kallel, A, Khera, A, Kostner, K, Kubilius, R, Latkovskis, G, John Mancini, GB, David Marais, A, Martin, SS, Martinez, JA, Mazidi, M, Mirrakhimov, E, Miserez, AR, Mitchenko, O, Mitkovskaya, NP, Moriarty, PM, Mohammad Nabavi, S, Nair, D, Panagiotakos, DB, Paragh, G, Pella, D, Petrulioniene, Z, Pirro, M, Postadzhiyan, A, Puri, R, Reda, A, Reiner, Ž, Radenkovic, D, Rakowski, M, Riadh, J, Richter, D, Serban, MC, Shehab, AMA, Shek, AB, Sirtori, CR, Stefanutti, C, Tomasik, T, Viigimaa, M, Valdivielso, P, Vohnout, B, von Haehling, S, Vrablik, M, Wong, ND, Yeh, HI, Zhisheng, J and Zirlik, A (2023) Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 189. ISSN 1043-6618

Preview

Text Nutraceutical approaches to non-alcoholic fatty liver diseaase - a positionpaper from the international lipid expert panel.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (2MB) | Preview

Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10–25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the disease. The suggestions for the management of NAFLD are like those recommended by guidelines for CVD prevention. In this context, the general approach is to prescribe physical activity and dietary changes the effect weight loss. Lifestyle change in the NAFLD patient has been supplemented in some by the use of nutraceuticals, but the evidence based for these remains uncertain. The aim of this Position Paper was to summarize the clinical evidence relating to the effect of nutraceuticals on NAFLD-related parameters. Our reading of the data is that whilst many nutraceuticals have been studied in relation to NAFLD, none have sufficient evidence to recommend their routine use; robust trials are required to appropriately address efficacy and safety.

Item Type:	Article
Uncontrolled Keywords:	International Lipid Expert Panel (ILEP); Humans; Liver Cirrhosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Lipids; Dietary Supplements; Adult; Child; Non-alcoholic Fatty Liver Disease; Dietary supplements; Liver steatosis; NAFLD; Nutraceuticals; Position paper; Adult; Child; Humans; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Dietary Supplements; Liver Cirrhosis; Cardiovascular Diseases; Lipids; 1115 Pharmacology and Pharmaceutical Sciences; Pharmacology & Pharmacy
Subjects:	R Medicine > RC Internal medicine R Medicine > RS Pharmacy and materia medica
Divisions:	Pharmacy & Biomolecular Sciences
Publisher:	Elsevier BV
SWORD Depositor:	A Symplectic
Date Deposited:	21 Jul 2023 08:35
Last Modified:	21 Jul 2023 08:45
DOI or ID number:	10.1016/j.phrs.2023.106679
URI:	https://researchonline.ljmu.ac.uk/id/eprint/20464

View Item